Immune Design Corp (IMDZ) Receives $16.00 Consensus PT from Analysts
Immune Design Corp (NASDAQ:IMDZ) has received a consensus rating of “Hold” from the seven research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $16.00.
A number of equities research analysts recently commented on IMDZ shares. Wells Fargo & Co downgraded Immune Design from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $29.00 to $10.00 in a report on Tuesday, October 17th. ValuEngine downgraded Immune Design from a “sell” rating to a “strong sell” rating in a report on Saturday, October 21st. Zacks Investment Research raised Immune Design from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a report on Monday, November 6th. Finally, Cowen reiterated a “buy” rating on shares of Immune Design in a research report on Monday, December 11th.
Immune Design (NASDAQ:IMDZ) remained flat at $$3.25 during trading on Friday. The stock had a trading volume of 354,100 shares, compared to its average volume of 588,269. Immune Design has a 12-month low of $2.90 and a 12-month high of $13.05. The stock has a market cap of $156.19, a price-to-earnings ratio of -1.53 and a beta of 2.03.
A number of hedge funds have recently made changes to their positions in IMDZ. Alliancebernstein L.P. purchased a new position in Immune Design during the second quarter valued at approximately $118,000. Virtu KCG Holdings LLC purchased a new stake in shares of Immune Design in the second quarter valued at approximately $153,000. Dimensional Fund Advisors LP increased its position in shares of Immune Design by 9.3% in the second quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock valued at $184,000 after buying an additional 1,600 shares in the last quarter. Rhumbline Advisers increased its position in shares of Immune Design by 53.9% in the second quarter. Rhumbline Advisers now owns 19,694 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 6,896 shares in the last quarter. Finally, New York State Common Retirement Fund increased its position in shares of Immune Design by 95.1% in the second quarter. New York State Common Retirement Fund now owns 20,100 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 9,799 shares in the last quarter. Institutional investors own 25.16% of the company’s stock.
About Immune Design
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.